Settlement Over Risperdal Marketing Would Include $400 Million Criminal Fine
BY JONATHAN D. ROCKOFF AND JOANN S. LUBLIN
Johnson & Johnson and federal prosecutors have reached a deal that would settle investigations into the company’s marketing practices for as much as $2.2 billion, including a roughly $400 million criminal fine for the illegal promotion of the antipsychotic Risperdal, according to people familiar with the matter.
The deal would preserve the health-care giant’s ability to sell its products to government health programs like Medicare and resolve other lingering investigations in addition to the Risperdal probe, while prosecutors could trumpet securing one of the biggest drug-marketing settlements.
The final sum will depend on which states suing J&J sign on to … Scarica il pdf: http://media.mimesi.com/cacheServer/servlet/CNcacheCopy?file=201207/20/0088_page-1262805733.html&authCookie=-1679654597
19 lug 2012